Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.61 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.43 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 4/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4592299 | 0.85 | PRMT6 (0.61) | PRMT6SCN10ACHRM5SCN5APIP4K2A | |
| SCHEMBL3602312 | 0.80 | ALDH1A1 (0.47) | CHRM5SCN5A | |
| SCHEMBL7393685 | 0.80 | CYP11B1 (0.56) | PRMT6CYP11B1CYP11B2 | |
| SCHEMBL4591289 | 0.80 | KIF11 (0.48) | PRMT6CYP11B1CYP11B2AKT1CA12 | |
| SCHEMBL21377112 | 0.78 | PRMT6 (0.54) | PRMT6SCN10ACHRM5PIP4K2AABL1 | |
| SCHEMBL4197241 | 0.77 | DRD2 (0.52) | SCN10ACYP11B1CYP11B2 | |
| SCHEMBL1230338 | 0.76 | CYP11B1 (0.53) | PRMT6SCN10ASCN5APIP4K2AABL1 | |
| SCHEMBL4591849 | 0.75 | MAP4K4 (0.49) | SCN10ACYP11B1CYP11B2 | |
| SCHEMBL1008825 | 0.74 | ALDH1A1 (0.51) | CHRM5 | |
| SCHEMBL3997703 | 0.74 | AKR1C2 (0.50) | SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429605-B2 | Phenylpyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-30 | — | — | US | disclosed |
| CN-101213186-A | Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-07-02 | — | — | CN | disclosed |
| EP-1912969-A1 | PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017169-A1 | PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032530-A1 | Phenylpyridine derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032530-A1 | Phenylpyridine derivatives | CYP3A5, QDPR, DPYD | PRMT6 1357/4885SCN10A 1868/4885CHRM5 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.